1153 Surgical Outcomes of Occipitocervical Fusion for Metastatic Disease at the Craniocervical Junction: 24 Years of Experience at a Tertiary Cancer Referral Center

View at publisher Summarise with VIRAT
Authors: Gil Kimchi, Laurence D. Rhines, Claudio Esteves Tatsui, Robert Y. North, Christopher A Alvarez-Breckenridge, Ian E. McCutcheon, Esteban Ramirez Ferrer, Rômulo Augusto Andrade de Almeida, Francisco Alfredo Call-Orellana, Juan Pablo Zuluaga
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Metastatic disease at the craniocervical junction is rare. Typically, patients present with disabling neck pain and instability. To date, limited data exists to guide treatment strategies. METHODS: Adult patients who underwent occipitocervical fusion for metastatic disease at a single institution between 2001 and 2024 were identified from a prospectively maintained database. Cases involving non-metastatic conditions were excluded. Collected preoperative variables included patient demographics, baseline performance status, prior radiation treatments, lesion location, pathology type, and the degree of epidural spinal cord compression. The primary outcome was pain control, evaluated using Neck Visual Analog Scale (VAS), and Morphine Milligram Equivalents (MME) at immediate, 6-week, 3-month, and final follow-up intervals. Complications were extracted from electronic medical records and analyzed for associations with predisposing risk factors. RESULTS: A total of 126 occipitocervical fusions were performed, with 57 patients treated for metastatic disease. Pain (mechanical or occipital neuralgia) was the most common presenting symptom (94.6%). Renal cell carcinoma (37.1%) was the most frequent metastatic histology. Pain outcomes showed significant improvement, with Neck-VAS scores decreasing from a median of 8 (IQR 5–10) preoperatively to 5 (IQR 3–7) by postoperative day 1, and further reductions to 3 (IQR 0–4) at 6 weeks, 1 (IQR 0-3) at 3 months and to 1 (IQR 0-3) by the final follow-up. MME decreased from a median of 88.8 preoperatively to 53.5 at the last follow-up. The overall complication rate was 13%, with 8.9% attributed to wound healing disturbances. Only three cases required revision surgery. Age over 60 trended toward increased complication risk (p = 0.06), though other factors were not significantly associated with complications. CONCLUSIONS: Occipitocervical fusion is a safe, effective option for managing painful metastases at the craniocervical junction. Showing an acceptable complication rate and significant pain relief. This series represents the largest reported on this condition.

Fields of Study & Subjects

Management of metastatic bone disease Cervical and Thoracic Myelopathy Spinal Fractures and Fixation Techniques

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
222–222
Publication date
26 March 2026
Language
EN